Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 24, 2014
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

Highly Efficient High-Throughput Transfection
Markus Zumbansen1, Allison St. Amand2, Devin Leake2, Ludger Altrogge1, and Herbert Müller-Hartmann1

Successful RNAi experiments and large-scale siRNA screens require efficient delivery of highly functional and specific nucleic acids including siRNA oligonucleotides, shRNA vectors, or micro RNAs into an appropriate cell system. Cell types relevant for immunological research, such as primary T cells and several suspension cell lines, are poorly accessible using reagent-based transfection approaches.

More information
Automated High Throughput Nucleofection®
Claudia Merz, Andreas Schroers, Eric Willimann

Using primary cells for RNAi based applications such as target identification or – validation, requires a highly efficient transfection technology in combination with a reliable and robust automation system. To accomplish these requirements we integrated the amaxa 96-well Shuttle® in a Tecan Freedom EVO® cell transfection workstation which is based on Tecan’s Freedom EVO® liquid handling platform and include all the necessary components and features for unattended cell transfection.

More information
DOCKING STUDIES OF A NEW HETEROCYCLIC METHYLTHIOMORPHOLIN PHENOLS DERIVATIVES AS ANTIHYPERTENSIVE DRUGS WITH ACE TARGET.CASE FESCDIPINE II
1V. Vázquez,1O. Vázquez, 1,2M.A.Balboa, 1A. Ma. Velázquez, 1V.H. Abrego, 1B.Camacho, 1L. Martínez, 1L.A. Torres, 1A. Ramírez, 1I.Martínez, 3R.López-Castañares, 1S.Díaz-Barriga, 4J. Bocanegra, 4Froylan Gómez-Laguna, 1F. Olvera, 1E.Angeles.

As part of the Drug Design in Medicinal Chemistry Program of the UNAM, new methylthiomorpholinphenol compounds with cardiovascular effect, were studied. One of them, FESCDIPINE II, was an excellent antihypertensive drug, that has low toxicity and preliminary studies indicate that the Angiotensin-converting enzyme (ACE) system is the biological target of this compound.

More information
Use of gamma scinitigraphy to understand inhaled device/formulation variables on delivery efficiency and
Peter Scholes and Karen Jones

Systemic delivery of both small molecules and macromolecules via inhaled therapies is an area of significant ongoing research1. The pulmonary route offers the physiological benefits of a highly vascularised, large surface area for absorption which can promote high bioavailability and a rapid onset of action. For biomolecules such as peptides, proteins and nucleic acid derivatives, inhaled drug delivery can also provide a viable alterative to intravenous administration.

More information
Quantifying the Impact of a Drug on Gastric Emptying: Measuring the Pharmacodynamic Effect in Clinical Trials
A Rankin, M Paterson, A Connor

Many drug classes are known to alter the rate of gastric emptying. Whilst there is no specific regulatory guidance requiring the impact of drugs on GE to be measured, it is important to fully understand the mode of action and the relationship between the pharmacokinetic profile and the pharmacodynamic response.

More information
Building Flexibility ino Phase I Protocols and Early Clinical Development Programs
Lloyd Stevens and Gareth King

The transition of a drug candidate into Phase I and other early drug development programs is undergoing considerable examination and change. This has largely been brought about by commercial and scientific drivers to reduce attrition rates coupled with an evolving regulatory environment, all of which encourage the pharmaceutical industry to build both scientific focus and flexibility into the drug development program.

More information
Evaluation of Human Regional Bioavailability to Assess Whether Modified Release Development is Feasible
A Connor, G King and K Jones

Many modified release (MR) oral formulations rely on bioavailability from the distal regions of the gastrointestinal (GI) tract (i.e. the ileum and colon). Therefore, by assessing the bioavailability of a drug following delivery to the distal intestines, it is possible to determine whether MR formulation development is achievable.

More information
Diagnostic Significance of microRNA Tumor Biomarkers in Fine Needle Aspirates (FNA) of Pancreatic Cancer
Martina Doleshal 1, Anna E. Szafranska 1, Hayward S. Edmunds 2, Gregory J. Tsongalis 2, Murray Korc 2 and Emmanuel Labourier 1

Collection of pancreatic fine needle aspirates (FNAs) in RNARetain™ allows stabilization and protection of RNA in tissues containing high levels of nucleases; Differential miRNA expression in pancreatic FNAs accurately classifies benign and malignant tissue; Combinations of miRNA and mRNA expression signatures improve the separation between normal tissue and chronic pancreatitis; microRNAs are suitable analytes for molecular characterization of fine needle aspirates from pancreatic tissues.

More information
Apoptosis Inducing Novel microRNA for Breast cancer and Hepatocellular Carcinoma
Arutselvan Natarajan, Sally J. DeNardo, Mark A. Zern, Senthil K. Venugopal

MicroRNA provides a mechanism to target cancer stem cells and restraint tumors cells permanently; this could lead to promising cancer therapeutics and imaging agents. Apoptosis inducing microRNA was identified to target HCC and breast cancer cells for imaging and therapy.

More information
<< 7 8 9 10 11 12 13 >>
Showing Results 91 - 100 of 153
Scientific News
Silencing the FOXP2 Speech Gene Causes Breast Cancer Cells to Metastasize
BIDMC investigators make the surprising discovery that a gene associated with speech and language is linked to advanced breast cancer.
Fast Modeling Of Cancer Mutations
New genome-editing technique enables rapid analysis of genes mutated in tumors.
New Test can Help Doctors Choose Best Treatment for Ovarian Cancer
ADNEX discriminate between benign and malignant tumours with a high level of accuracy.
All the Cell’s a Stage
Brian Strahl, PhD, and his band of biochemists unravel the complicated mysteries of the epigenetic code to find a culprit in cancer development.
New Cancer Drug To Begin Trials In Multiple Myeloma Patients
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.
ISB Gets $6.5 Million from NCI
Company has received two-year contract to create ‘Cancer Genomics Cloud’ with partners Google and SRA International.
Precise Control Over Genes Results from Game-Changing Research
UCSF invention greatly amplifies power of CRISPR technology.
Unusual Skin Cancer Linked To Chronic Allergy
Scientists have learned that inflammation at the site of an allergic skin rash can promote skin tumor formation if it persists.
New Clues For Early Colorectal Cancer Detection
Study identifies new biomarkers which could help detect colorectal cancer.
New 'Lab-on-a-Chip' Could Revolutionize Early Diagnosis of Cancer
Faster result times, reduced costs, minimal sample demands and better sensitivity of analysis.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv